Cover Image
市場調查報告書

血栓性血小板低下紫斑症:開發中產品分析

Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192851
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
血栓性血小板低下紫斑症:開發中產品分析 Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2016
出版日期: 2016年10月19日 內容資訊: 英文 74 Pages
簡介

血栓性血小板低下紫斑症是血液的難治之症,特徵是細微血管的內部血栓凝固(血栓症),血小板數減少。主要的症狀,是皮膚和粘膜的出血、混亂、發熱、頭痛、心律增加、呼吸急促、失語症、衰弱、黃疸等。主要的治療方法,包含脾臟摘出手術和免疫系抑制劑(皮質類固醇等)等。

本報告提供全球各國的血栓性血小板低下紫斑症治療用的開發中產品的開發情形相關分析,開發中產品的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等。

簡介

  • 調查範圍

血栓性血小板低下紫斑症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

血栓性血小板低下紫斑症:企業開發中的治療藥

血栓性血小板低下紫斑症:大學/機關研究中的治療藥

血栓性血小板低下紫斑症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

血栓性血小板低下紫斑症:企業開發中的產品

血栓性血小板低下紫斑症:大學/機關研究中的產品

血栓性血小板低下紫斑症的治療藥開發作的企業

  • Ablynx NV
  • Biogen, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Kaketsuken K.K.
  • Lee's Pharmaceutical Holdings Limited
  • Octapharma AG
  • Omeros Corporation

血栓性血小板低下紫斑症:治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

血栓性血小板低下紫斑症:最近的開發平台趨勢

血栓性血小板低下紫斑症:暫停中的計劃

血栓性血小板低下紫斑症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8561IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2016, provides an overview of the Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline landscape.

Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, heart rate, shortness of breath, speech changes, weakness and yellowish color to the skin (jaundice). Treatment includes surgery to remove spleen and drugs that suppress the immune system, such as corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 3 and 4 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Thrombotic Thrombocytopenic Purpura.

Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Thrombotic Thrombocytopenic Purpura Overview
  • Therapeutics Development
    • Pipeline Products for Thrombotic Thrombocytopenic Purpura - Overview
    • Pipeline Products for Thrombotic Thrombocytopenic Purpura - Comparative Analysis
  • Thrombotic Thrombocytopenic Purpura - Therapeutics under Development by Companies
  • Thrombotic Thrombocytopenic Purpura - Therapeutics under Investigation by Universities/Institutes
  • Thrombotic Thrombocytopenic Purpura - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Thrombotic Thrombocytopenic Purpura - Products under Development by Companies
  • Thrombotic Thrombocytopenic Purpura - Products under Investigation by Universities/Institutes
  • Thrombotic Thrombocytopenic Purpura - Companies Involved in Therapeutics Development
    • Ablynx NV
    • Biogen Inc
    • Glenmark Pharmaceuticals Ltd.
    • Hansa Medical AB
    • Kaketsuken K.K.
    • Lee's Pharmaceutical Holdings Limited
    • Octapharma AG
    • Omeros Corporation
  • Thrombotic Thrombocytopenic Purpura - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ARC-15105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAX-930 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • caplacizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GBR-600 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-721 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plasma (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Thrombotic Thrombocytopenic Purpura - Dormant Projects
  • Thrombotic Thrombocytopenic Purpura - Product Development Milestones
    • Featured News & Press Releases
      • Oct 11, 2016: First patient treated with IdeS in Phase II study in acquired Thrombotic Thrombocytopenic Purpura
      • Sep 29, 2016: Ablynx First-In-Class Wholly-Owned Anti-vWF Nanobody, Caplacizumab, May Have The Potential To Reduce Morbidity And Mortality Associated With Acquired TTP
      • May 26, 2016: Ablynx To Present A Post-Hoc Analysis Of The Phase II Titan Study With Caplacizumab In Acquired Ttp Patients At The 21St Congress Of The European Hematology Association
      • Feb 11, 2016: New England Journal Of Medicine Publishes Ablynx Phase II Titan Study Of Caplacizumab in Patients With Acquired TTP
      • Sep 29, 2015: Ablynx Initiates A Multinational Phase III Study With Caplacizumab In Patients With Acquired TTP
      • Jun 17, 2015: Ablynx Announces Presentations On Its Potential First-In-Class Treatment For Acquired TTP, Caplacizumab, At The 2015 Annual Meeting Of The ISTH
      • Feb 19, 2015: Omeros Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use
      • Dec 08, 2014: Additional Clinical Data From The Phase II Study With Ablynx'S Anti-Vwf Nanobody, Caplacizumab, Presented At The American Society Of Hematology Annual Meeting
      • Nov 26, 2014: Ablynx Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti Vwf nanobody, Caplacizumab
      • Jun 17, 2014: Ablynx's Anti-vWF Nanobody, Caplacizumab, achieves Clinical Proof-of-concept in Phase II Titan Study
      • Apr 03, 2014: Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies
      • Jul 28, 2011: Initial Observations Of ABLYNX'S PHASE II TTP Program Presented At ISTH Congress
      • Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For ALX-0081
      • Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For Thrombotic Thrombocytopenic Purpura
      • Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For Thrombotic Thrombocytopenic Purpura
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Thrombotic Thrombocytopenic Purpura, H2 2016
  • Number of Products under Development for Thrombotic Thrombocytopenic Purpura - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Thrombotic Thrombocytopenic Purpura - Pipeline by Ablynx NV, H2 2016
  • Thrombotic Thrombocytopenic Purpura - Pipeline by Biogen Inc, H2 2016
  • Thrombotic Thrombocytopenic Purpura - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
  • Thrombotic Thrombocytopenic Purpura - Pipeline by Hansa Medical AB, H2 2016
  • Thrombotic Thrombocytopenic Purpura - Pipeline by Kaketsuken K.K., H2 2016
  • Thrombotic Thrombocytopenic Purpura - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
  • Thrombotic Thrombocytopenic Purpura - Pipeline by Octapharma AG, H2 2016
  • Thrombotic Thrombocytopenic Purpura - Pipeline by Omeros Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Thrombotic Thrombocytopenic Purpura - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Thrombotic Thrombocytopenic Purpura, H2 2016
  • Number of Products under Development for Thrombotic Thrombocytopenic Purpura - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top